Physician profile
Irina Daniel
NPI 1669038709
$3,967.33
in general payments reported to CMS, 2019-2025
15 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $437 · 2021: $1,481 · 2022: $663 · 2023: $342 · 2024: $365 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,031.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $695.78 | 2020-2022 | |
| Eyevance Pharmaceuticals LLC | $567.52 | 2021-2022 | |
| Alcon Vision LLC | $491.00 | 2021-2025 | Tryptyr, Argos, Simbrinza |
| Sun Pharmaceutical Industries INC. | $456.38 | 2019-2024 | |
| Aerie Pharmaceuticals, INC. | $366.51 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $329.61 | 2023-2024 | Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $307.70 | 2019-2021 | |
| Harrow Eye, LLC | $169.54 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $167.26 | 2022-2023 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $118.46 | 2021 | |
| Mallinckrodt Hospital Products INC. | $92.99 | 2020 | |
| Abbvie INC. | $87.00 | 2022-2025 | |
| Mallinckrodt Enterprises LLC | $79.53 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $19.54 | 2025 | Xdemvy |
| Thea Pharma INC. | $18.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irina Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.